KB-1455

RO7200220-hIgG2-H311A

45724

Home » Antibodies » RO7200220-hIgG2-H311A

Background of RO7200220-hIgG2-H311A

RO7200220 is an anti-IL6 monoclonal antibody that is being investigated for the treatment of uveitic macular edema (UME) and diabetic macular edema (DME). The proposed mechanism of action for RO7200220 is to control inflammation and reduce fluid buildup in the retina, specifically for the treatment of uveitic macular edema and diabetic macular edema, without the side effects associated with steroid-based therapies.

Specifications

Catalog Number	KB-1455
Antibody Name	RO7200220-hIgG2-H311A
Isotype	Human IgG2,kappa
FC Muations	H311A
Target	IL6
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, et al. 2012. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180: 165–176.
Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11: 88–95.